Market review of medicines used in the treatment of hemophilia under the federal program “7 nosologies”
Hemophilia is one of the rare, socially significant, hereditary diseases drug supply of which centralized in the framework of the program “7 nosologies” at the expense of the Federal budget. According to IMS Health, in 2015 the consumption of medicinal drugs used in the treatment of hemophilia reached 11.2 billion RUB that shows an increase of 16.9% compared to 2010. The main drivers of market growth have become the primarily raising awareness of the disease and the increase in diagnosis led to growth of the patient population as a whole, as well as understanding of the need for effective and quality care that led to a rise of the prescription of the preventive therapy, in which a comparably larger consumption of the medicines for the patient leads to a significant improvement in outcomes and safety of patients. The improving of the quality of medical care is also implemented through the inclusion into the program of modern recombinant medicines, possessing the best safety profile in comparison to the medicines obtained from the plasma of donated blood. Every year the budgetary allocation for the treatment of high-cost nosology in general and for hemophilia increases, that indicates the primary focus of health aimed for improving of the quality of life of patients.
Скорее всего ваш браузер не поддерживает PDF и Adobe Reader, нажмите здесь, чтобы просмотреть PDF
Bibliography link: Yagudina R.I., Molchanova N. B. Market review of medicines used in the treatment of hemophilia under the federal program “7 nosologies” // Pharmacoeconomics: theory and practice. - 2016. - Vol.4, №4. - P.115-119 DOI: https://doi.org/10.30809/phe.4.2016.2